Zenith Epigenetics

Executive Summary

Zenith Epigenetics is a clinical-stage biotechnology company focused on developing best-in-class bromodomain and extra-terminal inhibitors (BETi) for oncology and other diseases with high unmet need. The company's lead candidate, ZEN-3694, is a potent and selective BET inhibitor currently in Phase 2 trials for multiple cancers, including metastatic castration-resistant prostate cancer (mCRPC) and triple-negative breast cancer (TNBC). By targeting epigenetic regulators, Zenith aims to overcome resistance to standard therapies and provide durable responses. The company has demonstrated early clinical activity and tolerability, positioning it as a potential leader in the BETi space. With a strong preclinical pipeline and a focus on rational combination strategies, Zenith Epigenetics represents a promising investment opportunity in targeted epigenetic therapeutics, though it remains private with no disclosed financing details.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for ZEN-3694 in mCRPC45% success
• TBDPotential partnership or licensing deal for ZEN-369430% success
• Q4 2026Initiation of Phase 3 trial planning or FDA meeting for lead indication40% success